May 22 (Reuters) -

Hinge Health and its selling stockholders raised $437.3

million in its U.S. initial public offering, the digital health

startup said on Wednesday, after pricing its shares at the

higher end of the marketed range.

The company sold about 8.52 million shares and its

shareholders, which include its largest investor, Insight

Partners, sold 5.14 million shares at $32 per share, compared

with its marketed range of $28 to $32 apiece.

Even at the top of its proposed range, Hinge Health's target

is nearly 52% lower than its $6.2 billion valuation from the

2021 Series E round, led by Coatue Management and Tiger Global.

The company will list on the New York Stock Exchange on

Thursday, under the symbol 'HNGE'.

Morgan Stanley, Barclays Capital and BofA Securities are the

lead underwriters for the offering.

Founded in 2014 by Daniel Perez and Gabriel Mecklenburg,

Hinge Health's platform leverages artificial intelligence to

provide at-home musculoskeletal care, chronic pain management,

and post-surgical rehabilitation.

De-escalation in the U.S.-China trade tensions has helped in

the revival of the IPO market, which saw a period of subdued

activity in early 2025.